# Plasma Protein Therapeutic Market

> Plasma Protein Therapeutic Market Research Report: Size, Share, Trend Analysis By Applications (Immunology, Hematology, Neurology, Oncology), By Product Type (Intravenous Immunoglobulin, Coagulation Factor Concentrates, Albumin, Alpha-1 Antitrypsin), By End Use (Hospitals, Homecare Settings, Ambulatory Surgical Centers), By Patient Type (Pediatric, Adult, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.17%
- **2024:** $ 28.7 Billion
- **2025:** $ 29.9 Billion
- **2035:** $ 44.98 Billion
- **Key Players:** Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), Octapharma (CH), Baxter International Inc. (US), Kedrion S.p.A. (IT), LFB S.A. (FR), Biotest AG (DE), Emergent BioSolutions Inc. (US)

**Report ID:** MRFR/HC/41568-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/plasma-protein-therapeutic-market-43234

---

## Market Summary

## **Plasma Protein Therapeutic Market Overview**

As per MRFR analysis, the Plasma Protein Therapeutic Market Size was estimated at 27.55 (USD Billion) in 2023.The Plasma Protein Therapeutic Market Industry is expected to grow from 28.7(USD Billion) in 2024 to 45.0 (USD Billion) by 2035. The Plasma Protein Therapeutic Market CAGR (growth rate) is expected to be around 4.17% during the forecast period (2025 - 2035).

### **Key Plasma Protein Therapeutic Market Trends Highlighted**

The Global Plasma Protein Therapeutic Market is driven by an increasing prevalence of chronic diseases and immune disorders requiring regular treatment. Advances in technology have led to more efficient and safer production methods for plasma-derived products, enhancing their availability. The growing awareness and acceptance of these therapies among patients and healthcare providers contribute significantly to market growth. Additionally, the rise in healthcare spending across various regions supports the market, as governments and institutions invest more in treating conditions with plasma protein therapies, further fueling demand.

There are numerous opportunities to be explored in this market, particularly in the area of research and development.

Innovations in product formulations and the development of new therapies for currently untreatable conditions can open new avenues for companies. Increased collaboration between pharmaceutical companies and research institutions can accelerate the introduction of novel therapies, leading to enhanced treatment options. Moreover, expanding into emerging markets presents significant growth potential, given the rising incidences of diseases and the increasing population that requires therapeutic interventions. Recent trends show a greater focus on personalized medicine, where treatments are tailored to individual patients based on genetic makeup or specific disease characteristics.

The rise in demand for immunoglobulins for autoimmune diseases and the steady increase in the usage of clotting factor concentrates in hemophilia patients further highlight evolving preferences in treatment strategies. Regulatory bodies continue to enhance guidelines for the approval of new therapies, pushing companies to invest more in compliance and standardized production processes. Overall, the combination of these dynamics illustrates a robust landscape with ongoing developments in the realm of plasma protein therapeutics.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Plasma Protein Therapeutic Market Drivers**

### **Increasing Incidence of Chronic Diseases**

The Global Plasma Protein Therapeutic Market Industry is significantly driven by the rising incidence of chronic diseases worldwide. Conditions such as hemophilia, immunodeficiency disorders, and liver diseases necessitate ongoing therapeutic interventions, thus creating a growing demand for plasma-derived therapies. Plasma protein therapeutics play a crucial role in managing these conditions effectively. As the global population ages, the prevalence of age-related diseases is also on the rise.

This demographic shift enhances the demand for plasma protein therapies, as older adults often experience multiple health challenges that require specialized treatments. Furthermore, advancements in diagnostics have led to better disease detection rates, propelling the need for therapeutic options that can be administered to patients promptly. A well-structured healthcare infrastructure in both developed and emerging economies supports the availability and accessibility of these therapies, further driving market growth.

The targeted treatment capabilities offered by plasma-derived products have always sparked immense interest among healthcare providers owing to how it was beneficial in improving patient outcomes. This led to the belief that effective treatment of chronic diseases will lead to an abnormal rise in the demand for therapy products, leading to ever-continued growth within the Global Plasma Protein Therapeutic Market.

### **Technological Advancements in Production Processes**

Technological innovations in the production processes of plasma-derived therapies significantly bolster the Global Plasma Protein Therapeutic Market Industry. Recent advancements in fractionation technologies, purification processes, and viral inactivation methods have enhanced the safety and efficacy of plasma products, ensuring higher yields and better quality. These technological improvements not only streamline manufacturing but also reduce production costs, thereby making therapies more affordable and accessible for patients.Consequently, these factors serve to enhance the overall market dynamics.

### **Growing Investment in Research and Development**

The increasing investment in research and development (R) within the Global Plasma Protein Therapeutic Market Industry serves as a notable driver for market growth. Companies are focused on exploring new therapy options, indications, and formulations through rigorous R&D efforts. This not only broadens the product pipeline but also helps in overcoming existing limitations of current therapies. As a result, innovative treatments are expected to enter the market, catering to unmet medical needs.

## **Plasma Protein Therapeutic Market Segment Insights**

### **Plasma Protein Therapeutic Market Application Insights**

The Global Plasma Protein Therapeutic Market, particularly within the Application segment, demonstrates a vast potential for growth and diversification. As of 2024, the overall market is projected to be valued at approximately 28.7 USD Billion, with a steady increase expected as the industry adapts to evolving healthcare needs. One of the most significant segments in **[Immunology](../../../reports/immunology-market-30261)**, valued at 8.5 USD Billion in 2024 and is anticipated to grow to 13.5 USD Billion by 2035, indicating its crucial role in addressing autoimmune disorders and inflammatory diseases, especially as advancements in immunotherapies gain traction.

Following closely is the Hematology segment, valued at 7.0 USD Billion in 2024 and expected to rise to 11.0 USD Billion by 2035, highlighting the essential function of plasma proteins in treating blood-related disorders, such as hemophilia, thereby illustrating the segment's importance to patient care and management. The Neurology application, holding a valuation of 6.0 USD Billion in 2024, is projected to increase to 9.0 USD Billion by 2035, underlining the critical need for plasma-derived therapies in rare neurological conditions and showcasing how innovations in this area can significantly improve patient outcomes.

The Oncology segment, valued at 7.2 USD Billion in 2024 and projected to grow to 11.5 USD Billion by 2035, highlights the applicability of plasma protein therapies in cancer treatment, particularly as supportive care options in combating treatment-associated deficiencies and improving overall patient well-being. Each of these segments contributes uniquely to the overall Global Plasma Protein Therapeutic Market revenue, with Immunology and Hematology significantly dominating and reflecting a robust market response to chronic and critical therapeutic needs.

The growth drivers across these applications stem from a rise in chronic diseases, advancements in therapeutic innovation, and increased adoption of personalized medicine. Mixed with the challenges of regulatory approvals and high treatment costs, these segments present a unique landscape filled with both significant opportunities and hurdles, which are essential for stakeholders navigating the Global Plasma Protein Therapeutic Market industry. Emphasizing the role of these applications not only illustrates the market's statistical growth but also emphasizes the necessity for continued research, development, and investment in plasma protein therapies to meet existing and emergent healthcare demands effectively.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Plasma Protein Therapeutic Market Product Type Insights**

The Global Plasma Protein Therapeutic Market is experiencing steady growth; within this market, the Product Type segment plays a crucial role, encompassing various essential products such as Intravenous Immunoglobulin, Coagulation Factor Concentrates, Albumin and Alpha-1 Antitrypsin. Intravenous Immunoglobulin is noteworthy for its significant application in treating immunodeficiency disorders, effectively influencing market dynamics. Coagulation Factor Concentrates are pivotal for hemophilia management, reflecting a substantial demand driven by rising patient populations and awareness.

Albumin, known for its vital role in maintaining oncotic pressure, also holds importance in therapeutic interventions, leading to a considerable market share. Meanwhile, Alpha-1 Antitrypsin serves as a critical treatment for lung diseases, further emphasizing its significance in patient care. The overall landscape of the Global Plasma Protein Therapeutic Market segmentation indicates a variety of opportunities, driven by increasing chronic diseases and advancements in treatment regimens, positioning the market for continuous growth as healthcare providers increasingly rely on these plasma-derived therapies.

### **Plasma Protein Therapeutic Market End Use Insights**

The Global Plasma Protein Therapeutic Market has been witnessing steady growth with its end-use segmentation playing a crucial role in shaping market dynamics. Hospitals aresignificant user of these therapies, emphasizing their importance in patient care and treatment efficacy, as they hold a majority while catering to a broad range of treatment options. Homecare settings are gaining traction, driven by the shift towards patient-centric care and the growing preference for convenient treatment options that enable patients to receive therapy in their own homes.

Ambulatory surgical centers also contribute significantly to the market growth, providing specialized care while minimizing hospital stays. With advancements in treatment protocols and an increasing prevalence of chronic diseases, the Global Plasma Protein Therapeutic Market is positioned for continued expansion. The market growth is supported by factors such as rising awareness about plasma therapies, an increase in product approvals, and ongoing research aimed at developing innovative treatments to meet patient needs.

However, challenges such as regulatory hurdles and the high costs of therapies remain.Overall, the Global Plasma Protein Therapeutic Market data reflects a robust landscape that continues to evolve alongside advancements in medical technology and patient care paradigms.

### **Plasma Protein Therapeutic Market Patient Type Insights**

The market statistics indicate a diverse spectrum of needs, where the Adult segment often shows a majority holding, reflecting the higher prevalence of disorders treated with plasma protein therapies in this demographic. Pediatric patients, while fewer in number, represent a crucial growth opportunity due to the need for specialized treatment options tailored to younger populations.

Geriatric patients are increasingly significant as the global aging population grows, leading to a rise in age-related diseases that require plasma-derived therapies. The market growth is driven by an increasing incidence of immunodeficiencies and other chronic conditions across these patient types, alongside innovations in manufacturing and distribution that enhance access to therapies. Challenges include regulatory hurdles and varying reimbursement policies across regions, but opportunities remain in developing therapies for niche populations within these segments.

Overall, the Global Plasma Protein Therapeutic Market segmentation highlights the importance of addressing the unique needs of different patient demographics to foster growth and improve patient outcomes.

### **Plasma Protein Therapeutic Market Regional Insights**

The Global Plasma Protein Therapeutic Market is projected to experience diverse growth across its regional segments. In 2024, North America is expected to hold a majority share, valued at 12.1 USD Billion, and will rise to 18.5 USD Billion by 2035, driven by advanced healthcare infrastructure and increased prevalence of plasma-related conditions. Europe follows with a valuation of 8.3 USD Billion in 2024, reaching 13.0 USD Billion in 2035, benefiting from robust regulatory support for plasma therapies.

The APAC region, valued at 5.4 USD Billion in 2024 and anticipated to grow to 8.5 USD Billion by 2035, shows significant potential due to rising healthcare demands and increased awareness about therapeutics.

South America and MEA, while currently smaller markets are expected to expand from 1.5 USD Billion to 2.3 USD Billion and from 1.4 USD Billion to 2.7 USD Billion, respectively, reflecting growing healthcare investments and improving access to treatments. Overall, the Global Plasma Protein Therapeutic Market data highlights a landscape where North America leads significantly, demonstrating the importance of this region in setting the trend and fostering innovation within the industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Plasma Protein Therapeutic Market Key Players and Competitive Insights**

The Global Plasma Protein Therapeutic Market has witnessed significant growth and diversity in recent years due to an increasing focus on advanced therapies and therapies derived from human plasma. This market comprises a range of products aimed at diseases such as hemophilia, immunodeficiencies, and neurological disorders, with plasma-derived therapies being pivotal for patient care. The competitive landscape is characterized by several key players who have established a robust foothold in the industry, leveraging their technological advances, extensive distribution networks, and strategic collaborations to meet the evolving needs of healthcare providers and patients alike.

As the demand for these therapies escalates, companies are increasingly focusing on innovation, regulatory compliance, and operational excellence to enhance their market positioning and capitalize on emerging opportunities within this dynamic environment.

Innovative Bioresearch has emerged as a notable contender within the Global Plasma Protein Therapeutic Market, recognized for its commitment to quality and patient-centered solutions. The company is distinguished by its advanced research capabilities and innovative manufacturing processes, which contribute to the development of high-quality plasma-derived therapeutics. These strengths are reflected in their ability to address unmet medical needs with a portfolio that emphasizes efficacy and safety. Additionally, Innovative Bioresearch is known for its strategic partnerships with healthcare providers and academic institutions to accelerate product development and improve access to treatments. 

This collaborative approach enhances their market presence and solidifies their reputation as a leader in the domain of plasma protein therapeutics. Their focus on customization and responsiveness to market demands positions them favorably against competitors.ADMA Biologics stands out in the Global Plasma Protein Therapeutic Market, particularly for its specialized focus on immunoglobulin-based therapies. The company is recognized for its extensive product pipeline and dedication to addressing the needs of patients with immunodeficiency disorders.

ADMA Biologics has invested significantly in its state-of-the-art manufacturing facilities, which adhere to the highest standards of quality control and regulatory compliance, ensuring that their products meet industry benchmarks. 

Their ability to produce high-purity immunoglobulin products has fostered a high degree of trust among healthcare professionals and patients. Furthermore, ADMA Biologics is strategically pursuing opportunities for growth through product differentiation and acquisitions, allowing them to expand their market share effectively. Their unique positioning within the market, along with a customer-centric approach, further underlines their potential to thrive amidst competition in the Global Plasma Protein Therapeutic Market.

### **Key Companies in the Plasma Protein Therapeutic Market Include**

- Innovative Bioresearch
- ADMA Biologics
- Baxalta
- **[Medicago](https://www.medicagogroup.com/products/immunological-kits)**
- Grifols
- Fresenius Kabi
- LFB
- Blood Centers of America
- CSL Behring
- Biotest
- Sanjivani
- Takeda Pharmaceutical
- Octapharma
- HemaCare
- Kedrion

## Plasma Protein Therapeutic Market Industry Developments

- **Q2 2024: Takeda Opens New Plasma-Derived Therapies Manufacturing Facility in Japan** Takeda announced the opening of a new manufacturing facility in Osaka, Japan, dedicated to the production of plasma-derived therapies, aiming to increase supply capacity and meet growing demand for plasma protein therapeutics.
- **Q2 2024: Grifols Receives FDA Approval for New Plasma Fractionation Plant in North Carolina** Grifols received approval from the U.S. FDA to begin operations at its new plasma fractionation facility in Clayton, North Carolina, expanding its production capabilities for plasma protein therapeutics.
- **Q2 2024: CSL Behring Announces Launch of New Immunoglobulin Therapy in Europe** CSL Behring launched a new intravenous immunoglobulin (IVIG) therapy in several European countries, expanding its plasma protein therapeutics portfolio for the treatment of immune deficiencies.
- **Q3 2024: Kedrion and Kamada Announce Strategic Partnership to Develop Plasma-Derived Therapies** Kedrion and Kamada entered into a strategic partnership to co-develop and commercialize new plasma-derived protein therapeutics, focusing on rare and orphan diseases.
- **Q3 2024: Octapharma Opens New Plasma Collection Center in the United States** Octapharma announced the opening of a new plasma collection center in Texas, USA, to support the growing need for plasma used in the production of plasma protein therapeutics.
- **Q4 2024: Biotest Receives European Commission Approval for New Albumin Product** Biotest AG received approval from the European Commission for its new albumin product, expanding its plasma protein therapeutics offerings in the European market.
- **Q4 2024: Grifols Completes Acquisition of Plasma Collection Centers in Canada** Grifols completed the acquisition of several plasma collection centers in Canada, strengthening its plasma sourcing network for the production of plasma protein therapeutics.
- **Q1 2025: CSL Behring Announces $200 Million Investment in New Plasma Fractionation Facility in Australia** CSL Behring announced a $200 million investment to build a new plasma fractionation facility in Melbourne, Australia, to increase production capacity for plasma protein therapeutics.
- **Q1 2025: Takeda Receives FDA Approval for Expanded Use of Plasma-Derived Therapy for CIDP** Takeda received U.S. FDA approval for the expanded use of its plasma-derived therapy for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
- **Q2 2025: Kamada Announces FDA Approval of Plasma-Derived Alpha-1 Antitrypsin Therapy** Kamada Ltd. received FDA approval for its plasma-derived alpha-1 antitrypsin therapy for the treatment of alpha-1 antitrypsin deficiency in the United States.
- **Q2 2025: Bio Products Laboratory Opens New Plasma Collection Center in Germany** Bio Products Laboratory (BPL) opened a new plasma collection center in Germany to support the supply chain for plasma protein therapeutics.
- **Q2 2025: Octapharma Receives EMA Approval for New Intravenous Immunoglobulin Product** Octapharma received approval from the European Medicines Agency (EMA) for its new intravenous immunoglobulin (IVIG) product, expanding its plasma protein therapeutics portfolio in Europe.

## **Plasma Protein Therapeutic Market Segmentation Insights**

### **Plasma Protein Therapeutic Market Application Outlook**

- Immunology
- Hematology
- Neurology
- Oncology

### **Plasma Protein Therapeutic Market Product Type Outlook**

- Intravenous Immunoglobulin
- Coagulation Factor Concentrates
- Albumin
- Alpha-1 Antitrypsin

### **Plasma Protein Therapeutic Market End Use Outlook**

- Hospitals
- Homecare Settings
- Ambulatory Surgical Centers

### **Plasma Protein Therapeutic Market****Patient Type Outlook**

- Pediatric
- Adult
- Geriatric

### **Plasma Protein Therapeutic Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Growing Geriatric Population

The aging population is a significant driver of the Plasma Protein Therapeutic Market. As individuals age, they become more susceptible to various health conditions, including immune deficiencies and chronic diseases that often require plasma-derived therapies. The World Health Organization projects that the number of people aged 60 years and older will reach 2 billion by 2050, highlighting a substantial market opportunity. This demographic shift is likely to increase the demand for immunoglobulin therapies and other plasma protein products, as older adults often require more frequent medical interventions. Consequently, pharmaceutical companies and healthcare providers must focus on developing targeted therapies that cater to the unique needs of this population within the Plasma Protein Therapeutic Market.

### Regulatory Support for Plasma-Derived Therapies

Regulatory bodies are increasingly recognizing the importance of plasma-derived therapies, which is positively impacting the Plasma Protein Therapeutic Market. Initiatives aimed at streamlining the approval process for new therapies and enhancing safety standards are fostering innovation and encouraging investment in this sector. For example, the introduction of expedited review pathways for breakthrough therapies allows for faster access to life-saving treatments for patients. This regulatory support not only boosts confidence among manufacturers but also ensures that patients receive timely access to essential therapies. As a result, the Plasma Protein Therapeutic Market is likely to witness accelerated growth, driven by a favorable regulatory environment that promotes the development and commercialization of new plasma-derived products.

### Increasing Investment in Research and Development

Investment in research and development (R&D) is a critical driver of the Plasma Protein Therapeutic Market. Pharmaceutical companies are allocating substantial resources to discover and develop novel therapies that leverage the therapeutic potential of plasma proteins. This focus on R&D is essential for addressing unmet medical needs and improving existing treatment options. Recent data indicates that R&D spending in the biopharmaceutical sector has reached unprecedented levels, with many companies prioritizing plasma-derived therapies. This trend is likely to result in the introduction of innovative products that enhance patient outcomes and expand the therapeutic applications of plasma proteins. As the industry continues to evolve, sustained investment in R&D will be pivotal in shaping the future landscape of the Plasma Protein Therapeutic Market.

### Technological Innovations in Plasma Fractionation

Technological advancements in plasma fractionation are significantly influencing the Plasma Protein Therapeutic Market. Innovations such as improved separation techniques and enhanced purification processes are leading to higher yields and better quality of plasma-derived products. For instance, the introduction of chromatography and membrane filtration technologies has streamlined the production process, resulting in more efficient extraction of immunoglobulins and clotting factors. This not only increases the availability of essential therapies but also reduces production costs, making treatments more accessible. As the industry continues to evolve, these technological innovations are expected to play a crucial role in meeting the rising demand for plasma protein therapies, thereby shaping the future of the Plasma Protein Therapeutic Market.

### Rising Incidence of Hemophilia and Other Rare Disorders

The Plasma Protein Therapeutic Market is experiencing a notable surge due to the increasing incidence of hemophilia and other rare disorders. Hemophilia A and B, which require regular infusions of clotting factor concentrates, are becoming more prevalent, thereby driving demand for plasma-derived therapies. According to recent estimates, the prevalence of hemophilia is approximately 1 in 5,000 male births, indicating a substantial patient population reliant on these therapies. This growing patient base necessitates the expansion of treatment options within the Plasma Protein Therapeutic Market, as healthcare providers seek to improve patient outcomes and quality of life. Furthermore, advancements in treatment protocols and the introduction of new therapies are likely to enhance the market landscape, making it imperative for stakeholders to adapt to these evolving needs.

## Future Outlook

The Plasma Protein Therapeutic Market is projected to grow at a 4.17% CAGR from 2025 to 2035, driven by increasing demand for immunoglobulin therapies and advancements in manufacturing technologies.

**New opportunities:**

- Expansion into emerging markets through strategic partnerships Development of personalized plasma therapies for niche conditions Investment in automated plasma collection technologies to enhance efficiency

By 2035, the market is expected to solidify its position as a leader in biopharmaceutical innovations.

## Segment Insights

### By Application: Immunology (Largest) vs. Oncology (Fastest-Growing)

In the Plasma Protein Therapeutic Market, the application segment is primarily dominated by [immunology](https://www.marketresearchfuture.com/reports/immunology-market-30261), which holds a substantial market share. This segment encompasses various therapies that leverage plasma-derived proteins to treat immune disorders, thereby reinforcing its position as the largest application. Other significant segments include hematology and neurology, but they do not capture the same level of market interest and share as immunology, primarily due to the broader range and higher prevalence of immune-related disorders that require plasma protein therapies. The growth trends for the plasma protein therapeutic applications reflect a dynamic landscape, particularly with oncology emerging as the fastest-growing segment. This shift is driven by an increasing incidence of cancer globally, leading to surges in demand for innovative therapies that utilize plasma proteins. Additionally, advancements in technology and more extensive research into plasma-derived treatments fuel the development of targeted therapies in oncology, paving the way for growth and investment within this segment.

Immunology (Dominant) vs. Oncology (Emerging)

Immunology remains the dominant application in the Plasma Protein Therapeutic Market, characterized by its extensive array of treatments for a variety of autoimmune diseases and related conditions. This segment benefits from established protocols and significant healthcare provider familiarity, contributing to its leadership in the market. Conversely, oncology is quickly becoming an emerging focus area due to rising cancer incidences and growing awareness regarding the role of plasma protein therapies in adjunctive treatments. While immunology therapies tend to be broadly applicable with established patient bases, oncology applications are experiencing transformative developments as novel therapies relying on plasma proteins show considerable clinical promise, compelling stakeholders to increase investments in this evolving sector.

### By Product Type: Intravenous Immunoglobulin (Largest) vs. Coagulation Factor Concentrates (Fastest-Growing)

The Plasma Protein Therapeutic Market is dynamically segmented, with Intravenous Immunoglobulin (IVIG) leading in market share due to its extensive use in treating various immunodeficiency disorders and autoimmune diseases. Coagulation Factor Concentrates, vital for hemophilia treatment, follow closely but are recognized as the fastest-growing segment driven by advancements in biotechnology and increasing awareness of hemophilia treatments. Additionally, Albumin and Alpha-1 Antitrypsin also play significant roles but have comparatively lower market shares than IVIG and Coagulation Factor Concentrates. Growth trends in the Plasma Protein Therapeutic Market suggest a robust future for both IVIG and Coagulation Factor Concentrates. The increasing prevalence of autoimmune diseases and hemophilia drives demand, while manufacturers focus on enhancing the efficacy and safety of these therapies through biotechnology innovations. Additionally, the rise in healthcare expenditure and supportive regulatory frameworks contribute to accelerating the growth trajectories of these segments, especially for Coagulation Factor Concentrates, which may see burgeoning interest from new entrants and investors.

Intravenous Immunoglobulin (Dominant) vs. Albumin (Emerging)

Intravenous Immunoglobulin (IVIG) remains the dominant player in the Plasma Protein Therapeutic Market. Its widespread applications, particularly in treating conditions such as primary immunodeficiency and certain autoimmune disorders, ensure consistent demand. Furthermore, its proven track record and established treatment protocols solidify its market leader status. On the other hand, Albumin emerges as a growing segment, increasingly recognized for its critical role in treating conditions like liver cirrhosis and burn injuries. Though historically overshadowed by IVIG, advancements in therapeutic formulations and increasing awareness of Albumin's therapeutic potential position it for growth. The competitive landscape for Albumin indicates significant opportunities, especially as research continues to unveil new applications and improve production efficiencies, reflecting an evolving market.

### By End Use: Hospitals (Largest) vs. Homecare Settings (Fastest-Growing)

In the Plasma Protein Therapeutic Market, hospitals have established a dominant position. They account for a significant share of the market due to their capacity to handle complex plasma-derived therapies and the availability of comprehensive care facilities. Homecare settings, although smaller currently, are quickly gaining traction, fueled by patient preference for at-home treatment options and advancements in medical technology that enable effective monitoring and therapy administration outside traditional hospital settings.

Hospitals (Dominant) vs. Homecare Settings (Emerging)

Hospitals represent the dominant segment in the Plasma Protein Therapeutic Market, characterized by their extensive resources, advanced facilities, and capability to deploy sophisticated treatments requiring specialized oversight. Offering a wide range of therapies, they remain a reliable source for patients needing immediate or intensive interventions. Conversely, homecare settings are emerging as a fast-growing alternative, driven by convenience and the push for patient-centric care. These settings are becoming increasingly equipped to deliver plasma therapies, allowing for greater flexibility in treatment schedules. As technological innovations continue to enhance at-home therapeutic delivery, this segment is poised to expand significantly, targeting the growing patient population seeking effective outpatient solutions.

### By Patient Type: Adult (Largest) vs. Pediatric (Fastest-Growing)

In the Plasma Protein Therapeutic Market, the patient type segmentation is crucial for understanding therapeutic needs. The adult patient group currently dominates the market, accounting for the largest share. This is largely due to the increasing prevalence of chronic diseases among adults, driving the demand for plasma-derived therapies. Meanwhile, the pediatric segment is emerging as the fastest-growing area, fueled by a heightened focus on treating rare pediatric conditions with targeted therapies and the overall growth in healthcare access across various regions.

Patient Type: Adult (Dominant) vs. Pediatric (Emerging)

The adult patient segment represents a significant portion of the Plasma Protein Therapeutic Market, driven by the rising incidences of autoimmune disorders and hemophilia, which require ongoing treatment with plasma-derived proteins. Adults benefit from established therapies and a robust healthcare infrastructure. In contrast, the pediatric segment is gaining traction as novel therapies tailored for children enter the market. This growth is supported by advancements in clinical research specifically aimed at pediatric applications, leading to the development of safer and effective treatments that cater to children's unique physiological needs. As a result, the pediatric segment is set to expand rapidly, showcasing the evolving landscape of plasma proteins in therapeutic applications.

## Regional Market Share Analysis

The Global Plasma Protein Therapeutic Market is projected to experience diverse growth across its regional segments. In 2024, North America is expected to hold a majority share, valued at 12.1 USD Billion, and will rise to 18.5 USD Billion by 2035, driven by advanced healthcare infrastructure and increased prevalence of plasma-related conditions. Europe follows with a valuation of 8.3 USD Billion in 2024, reaching 13.0 USD Billion in 2035, benefiting from robust regulatory support for plasma therapies.

The APAC region, valued at 5.4 USD Billion in 2024 and anticipated to grow to 8.5 USD Billion by 2035, shows significant potential due to rising healthcare demands and increased awareness about therapeutics.

South America and MEA, while currently smaller markets are expected to expand from 1.5 USD Billion to 2.3 USD Billion and from 1.4 USD Billion to 2.7 USD Billion, respectively, reflecting growing healthcare investments and improving access to treatments. Overall, the Global Plasma Protein Therapeutic Market data highlights a landscape where North America leads significantly, demonstrating the importance of this region in setting the trend and fostering innovation within the industry.

## Competitive Benchmarking

The Global Plasma Protein Therapeutic Market has witnessed significant growth and diversity in recent years due to an increasing focus on advanced therapies and therapies derived from human plasma. This market comprises a range of products aimed at diseases such as hemophilia, immunodeficiencies, and neurological disorders, with plasma-derived therapies being pivotal for patient care. The competitive landscape is characterized by several key players who have established a robust foothold in the industry, leveraging their technological advances, extensive distribution networks, and strategic collaborations to meet the evolving needs of healthcare providers and patients alike.As the demand for these therapies escalates, companies are increasingly focusing on innovation, regulatory compliance, and operational excellence to enhance their market positioning and capitalize on emerging opportunities within this dynamic environment.Innovative Bioresearch has emerged as a notable contender within the Global Plasma Protein Therapeutic Market, recognized for its commitment to quality and patient-centered solutions. The company is distinguished by its advanced research capabilities and innovative manufacturing processes, which contribute to the development of high-quality plasma-derived therapeutics. These strengths are reflected in their ability to address unmet medical needs with a portfolio that emphasizes efficacy and safety. Additionally, Innovative Bioresearch is known for its strategic partnerships with healthcare providers and academic institutions to accelerate product development and improve access to treatments. This collaborative approach enhances their market presence and solidifies their reputation as a leader in the domain of plasma protein therapeutics. Their focus on customization and responsiveness to market demands positions them favorably against competitors.ADMA Biologics stands out in the Global Plasma Protein Therapeutic Market, particularly for its specialized focus on immunoglobulin-based therapies. The company is recognized for its extensive product pipeline and dedication to addressing the needs of patients with immunodeficiency disorders.ADMA Biologics has invested significantly in its state-of-the-art manufacturing facilities, which adhere to the highest standards of quality control and regulatory compliance, ensuring that their products meet industry benchmarks. Their ability to produce high-purity immunoglobulin products has fostered a high degree of trust among healthcare professionals and patients. Furthermore, ADMA Biologics is strategically pursuing opportunities for growth through product differentiation and acquisitions, allowing them to expand their market share effectively. Their unique positioning within the market, along with a customer-centric approach, further underlines their potential to thrive amidst competition in the Global Plasma Protein Therapeutic Market.

## Recent News & Developments

- **Q2 2024: Takeda Opens New Plasma-Derived Therapies Manufacturing Facility in Japan** Takeda announced the opening of a new manufacturing facility in Osaka, Japan, dedicated to the production of plasma-derived therapies, aiming to increase supply capacity and meet growing demand for plasma protein therapeutics.
- **Q2 2024: Grifols Receives FDA Approval for New Plasma Fractionation Plant in North Carolina** Grifols received approval from the U.S. FDA to begin operations at its new plasma fractionation facility in Clayton, North Carolina, expanding its production capabilities for plasma protein therapeutics.
- **Q2 2024: CSL Behring Announces Launch of New Immunoglobulin Therapy in Europe** CSL Behring launched a new intravenous immunoglobulin (IVIG) therapy in several European countries, expanding its plasma protein therapeutics portfolio for the treatment of immune deficiencies.
- **Q3 2024: Kedrion and Kamada Announce Strategic Partnership to Develop Plasma-Derived Therapies** Kedrion and Kamada entered into a strategic partnership to co-develop and commercialize new plasma-derived protein therapeutics, focusing on rare and orphan diseases.
- **Q3 2024: Octapharma Opens New Plasma Collection Center in the United States** Octapharma announced the opening of a new plasma collection center in Texas, USA, to support the growing need for plasma used in the production of plasma protein therapeutics.
- **Q4 2024: Biotest Receives European Commission Approval for New Albumin Product** Biotest AG received approval from the European Commission for its new albumin product, expanding its plasma protein therapeutics offerings in the European market.
- **Q4 2024: Grifols Completes Acquisition of Plasma Collection Centers in Canada** Grifols completed the acquisition of several plasma collection centers in Canada, strengthening its plasma sourcing network for the production of plasma protein therapeutics.
- **Q1 2025: CSL Behring Announces $200 Million Investment in New Plasma Fractionation Facility in Australia** CSL Behring announced a $200 million investment to build a new plasma fractionation facility in Melbourne, Australia, to increase production capacity for plasma protein therapeutics.
- **Q1 2025: Takeda Receives FDA Approval for Expanded Use of Plasma-Derived Therapy for CIDP** Takeda received U.S. FDA approval for the expanded use of its plasma-derived therapy for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
- **Q2 2025: Kamada Announces FDA Approval of Plasma-Derived Alpha-1 Antitrypsin Therapy** Kamada Ltd. received FDA approval for its plasma-derived alpha-1 antitrypsin therapy for the treatment of alpha-1 antitrypsin deficiency in the United States.
- **Q2 2025: Bio Products Laboratory Opens New Plasma Collection Center in Germany** Bio Products Laboratory (BPL) opened a new plasma collection center in Germany to support the supply chain for plasma protein therapeutics.
- **Q2 2025: Octapharma Receives EMA Approval for New Intravenous Immunoglobulin Product** Octapharma received approval from the European Medicines Agency (EMA) for its new intravenous immunoglobulin (IVIG) product, expanding its plasma protein therapeutics portfolio in Europe.

## Report Scope

| MARKET SIZE 2024 | 28.7(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 29.9(USD Billion) |
| MARKET SIZE 2035 | 44.98(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.17% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), Octapharma (CH), Baxter International Inc. (US), Kedrion S.p.A. (IT), LFB S.A. (FR), Biotest AG (DE), Emergent BioSolutions Inc. (US) |
| Segments Covered | Applications, Product Type, End Use, Patient Type, Regional |
| Key Market Opportunities | Advancements in gene therapy and personalized medicine enhance growth potential in the Plasma Protein Therapeutic Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the Plasma Protein Therapeutic Market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Plasma Protein Therapeutic Market by 2035?**
A: The Plasma Protein Therapeutic Market is projected to reach a valuation of 44.98 USD Billion by 2035.

**Q: What was the market valuation of the Plasma Protein Therapeutic Market in 2024?**
A: In 2024, the Plasma Protein Therapeutic Market was valued at 28.7 USD Billion.

**Q: What is the expected CAGR for the Plasma Protein Therapeutic Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Plasma Protein Therapeutic Market during the forecast period 2025 - 2035 is 4.17%.

**Q: Which application segment is projected to have the highest valuation by 2035?**
A: The Oncology application segment is projected to reach a valuation of 17.98 USD Billion by 2035.

**Q: What are the projected revenues for Intravenous Immunoglobulin by 2035?**
A: By 2035, the projected revenues for Intravenous Immunoglobulin are expected to be between 19.0 USD Billion.

**Q: Which key players are leading the Plasma Protein Therapeutic Market?**
A: Key players in the Plasma Protein Therapeutic Market include Grifols, CSL Behring, and Takeda Pharmaceutical Company Limited.

**Q: What is the expected market size for the Adult patient type segment by 2035?**
A: The Adult patient type segment is expected to reach a market size of 26.0 USD Billion by 2035.

**Q: How does the market size for Coagulation Factor Concentrates compare to Albumin by 2035?**
A: By 2035, Coagulation Factor Concentrates are projected to reach 12.0 USD Billion, whereas Albumin is expected to reach 8.0 USD Billion.

**Q: What is the projected market size for Homecare Settings by 2035?**
A: The market size for Homecare Settings is projected to be between 12.0 USD Billion by 2035.

**Q: What is the expected growth trend for the Plasma Protein Therapeutic Market in the coming years?**
A: The Plasma Protein Therapeutic Market is expected to experience steady growth, driven by an anticipated CAGR of 4.17% from 2025 to 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/plasma-protein-therapeutic-market-43234*